Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?

(2014) Adriana Balduzzi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

(2014) K R Schultz et al.   LEUKEMIA

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation

(2013) G M Marshall et al.   LEUKEMIA

The MLL recombinome of acute leukemias in 2013

(2013) C Meyer et al.   LEUKEMIA

Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review

(2013) Marion K. Mateos et al.   PEDIATRIC BLOOD & CANCER

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

(2012) N. Gokbuget et al.   BLOOD

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

(2012) W. Leung et al.   BLOOD

Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies

(2012) R Bajwa et al.   BONE MARROW TRANSPLANTATION

Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

(2012) Stephen P. Hunger et al.   JOURNAL OF CLINICAL ONCOLOGY

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion

(2011) N C Venn et al.   LEUKEMIA

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

(2010) Catriona Parker et al.   LANCET

Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia

(2010) E Waanders et al.   LEUKEMIA

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation

(2010) A C Lankester et al.   LEUKEMIA

Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation

(2010) Ted A. Gooley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Approaches to Prevent Leukemia Relapse Following Allogeneic Hematopoietic Cell Transplantation

(2010) Michael R. Verneris et al.   Current Hematologic Malignancy Reports

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313

(2009) M. A. Pulsipher et al.   BLOOD

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia

(2009) Rosemary Sutton et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation

(2009) H Kreyenberg et al.   LEUKEMIA

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

Transplantation in adult ALL

(2009) A. H. Goldstone et al.   Hematology-American Society of Hematology Education Program

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL

(2008) E Fronkova et al.   BONE MARROW TRANSPLANTATION

Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials

(2008) A Schrauder et al.   BONE MARROW TRANSPLANTATION

Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time

(2008) A. Balduzzi et al.   HAEMATOLOGICA

Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

(2008) Peter Bader et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-κ and heavy-chain gene rearrangements

(2008) R Sutton et al.   LEUKEMIA

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia

(2008) T Flohr et al.   LEUKEMIA

Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia

(2008) R Sutton et al.   LEUKEMIA

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

(2008) Charles G. Mullighan et al.   NATURE